What Meds Cannot Be Taken With Melatonin?

Melatonin is sold over the counter and marketed as a natural sleep aid, which leads many people to assume it is interaction-free. It is not. 354 drugs are known to interact with melatonin — including 5 major interactions — making a pharmacist review essential before you add it to any existing medication routine. If you are currently taking a prescription drug and considering melatonin, this guide tells you what to look for and what to discuss with your healthcare team.

Table of Contents

• 1. Why Melatonin Interacts With So Many Drugs
• 2. Antidepressants: The Highest-Risk Category
• 3. Blood Thinners and Anticoagulants
• 4. Blood Pressure Medications
• 5. Sedatives, Sleep Aids, and CNS Depressants
• 6. Diabetes Medications and Immunosuppressants
• 7. Starting Low: Why Dose Precision Matters When You're on Medication
• Frequently Asked Questions
• Conclusion
• Research References

1. Why Melatonin Interacts With So Many Drugs

Most people assume that because melatonin is a hormone the body produces naturally, supplementing with it should be pharmacologically neutral. The reality is more complicated. According to StatPearls, melatonin undergoes extensive first-pass metabolism in the liver, primarily through the enzyme CYP1A2, with over 80% of an oral dose excreted as the inactive metabolite 6-sulfatoxymelatonin. This single metabolic pathway is shared with dozens of common prescription medications — and that is the root cause of most interactions.

The interactions fall into two broad mechanical categories. In the first, a drug inhibits CYP1A2, slowing melatonin's clearance and raising its blood concentration — sometimes dramatically. In the second, melatonin's biological effects (on blood pressure, blood glucose, immune activation, and coagulation) overlap or compete with the intended effects of another drug. A 2003 pharmacokinetic study confirmed that caffeine — one of the most common CYP1A2 substrates — increased melatonin's peak plasma concentration by 137% and total bioavailability by 120% when both were taken together. That figure comes from a standard coffee-sized dose, not a clinical outlier.

Understanding this enzyme-level mechanism is practically important for anyone on medication. If your prescriber has ever described one of your drugs as a "CYP1A2 inhibitor" or "CYP1A2 substrate," that drug almost certainly belongs on a pharmacist's interaction review before you add melatonin. The 7 major drug categories below carry the most clinically significant evidence.

2. Antidepressants: The Highest-Risk Category

Antidepressants represent the most thoroughly documented and mechanistically understood category of melatonin drug interactions. The interaction risk is not uniform across the drug class — it is enzyme-specific. A peer-reviewed study in the European Journal of Clinical Pharmacology demonstrated that fluvoxamine (Luvox), an SSRI that potently inhibits CYP1A2, markedly increased melatonin serum levels — while citalopram, another SSRI that does not inhibit CYP1A2, had no measurable effect. The class matters less than the enzyme profile of the specific drug.

The magnitude of the fluvoxamine interaction is clinically significant. Professional pharmacokinetic data from Drugs.com documents that fluvoxamine increased melatonin's total systemic exposure (AUC) by 17-fold and peak plasma concentration by 12-fold. That means a 1.5mg dose of melatonin could behave like 18–25mg in someone taking fluvoxamine — producing excessive sedation, next-day drowsiness, and unpredictable effects on sleep architecture. Oral contraceptives containing ethinyl estradiol, which also inhibit CYP1A2, can increase melatonin concentration by 4–5x.

Antidepressants in the following categories require careful review before combining with melatonin:

• SSRIs with CYP1A2 inhibition: Fluvoxamine (Luvox) — the highest-risk single drug in the entire melatonin interaction profile
• Tricyclic antidepressants (TCAs): Nortriptyline, amitriptyline — both CYP1A2 substrates; combined use is associated with a documented case report of severe sedation
• MAOIs: Affect melatonin metabolism through multiple pathways; considered high-risk; always require prescriber consultation
• SNRIs and other SSRIs: Lower individual risk, but potential for additive sedation still warrants a pharmacist check

3. Blood Thinners and Anticoagulants

Melatonin has a pharmacodynamic effect on coagulation that makes it clinically relevant for anyone on blood thinners. A placebo-controlled study published in the Journal of Pineal Research found that a single dose of oral melatonin lowered plasma levels of procoagulant factors in healthy young men, with evidence of a dose-response relationship. When combined with warfarin or other anticoagulants, this effect can amplify the drug's blood-thinning action beyond the intended therapeutic range.

Clinical data support this concern. A case series of 10 patients at Massachusetts General Hospital who received both melatonin and warfarin concurrently found that most patients experienced increases in INR (international normalized ratio) and prothrombin time — two standard measures of clotting activity — compared to their pre-melatonin baselines. GoodRx's pharmacist review notes that no cases of life-threatening bleeding have been reported from this interaction, but that patients on warfarin should notify their prescriber before starting melatonin, as more frequent INR monitoring is typically warranted. The interaction risk extends beyond warfarin to the full anticoagulant category:

• Vitamin K antagonists: Warfarin (Coumadin) — best-documented melatonin interaction in this class
• Antiplatelet agents: Aspirin (high-dose), clopidogrel (Plavix), ticagrelor (Brilinta)
• Low-molecular-weight heparins: Enoxaparin (Lovenox), dalteparin (Fragmin)
• Novel oral anticoagulants (NOACs): Dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis)

4. Blood Pressure Medications

The interaction between melatonin and blood pressure medications is bidirectional — melatonin can both reduce blood pressure (adding to the effect of antihypertensives in a way that risks hypotension) and, in the specific case of nifedipine, reduce the drug's effectiveness and raise blood pressure instead. Both outcomes create clinical problems, and the direction of the effect depends on which drug class is involved. The Mayo Clinic advises that melatonin might worsen blood pressure control in people taking antihypertensive medications and recommends discussing the combination with a prescriber.

The nifedipine interaction is the most quantified. A controlled study cited by GoodRx found that 5mg of melatonin taken alongside nifedipine (a calcium channel blocker used for hypertension) raised systolic blood pressure by 6.5 mmHg and diastolic pressure by 4.5 mmHg — sufficient to meaningfully counteract the medication's therapeutic purpose. The proposed mechanism is direct competition between melatonin and nifedipine at the calcium channel receptor, reducing the drug's receptor binding. Clinical pharmacists at GoodRx recommend that anyone on blood pressure medication discuss melatonin with their prescriber, who may suggest more frequent blood pressure monitoring or an alternative sleep approach.

Blood pressure drugs that warrant review before combining with melatonin include calcium channel blockers (nifedipine, amlodipine), beta-blockers (atenolol, metoprolol, propranolol), ACE inhibitors, and angiotensin receptor blockers. Beta-blockers carry an additional complexity: some beta-blockers suppress the body's own melatonin production, meaning patients on these drugs often have naturally lower melatonin levels — which is sometimes the reason they were considering supplementation in the first place. This context matters when assessing dose.

5. Sedatives, Sleep Aids, and CNS Depressants

Melatonin is itself a sedating compound. When combined with other medications or substances that depress the central nervous system, the sedative effects are additive — resulting in excessive drowsiness, impaired reaction time, next-day cognitive impairment, and, at extreme ends, respiratory depression risk. This category is broad and includes many commonly prescribed drugs. The Mayo Clinic flags CNS depressants as a category to use with caution when taking melatonin, with additive sedation as the primary concern.

The combinations most commonly flagged in clinical practice include benzodiazepines (diazepam, alprazolam, lorazepam), Z-drugs (zolpidem/Ambien, zaleplon), opioid pain medications, sedating antihistamines (diphenhydramine/Benadryl), and certain antidepressants with sedating profiles (trazodone, amitriptyline, mirtazapine). For someone already taking a prescription sleep aid, adding melatonin is rarely appropriate as a simultaneous combination — the goal in most clinical contexts is to use melatonin as a gradual transition away from sedative-hypnotics, not in parallel with them. StatPearls notes that melatonin's favorable adverse event profile — daytime sleepiness in 1.66% of users, headache in 0.74% — makes it an attractive alternative to prescription sedatives, but the transition should be medically supervised.

6. Diabetes Medications and Immunosuppressants

Melatonin has measurable effects on insulin sensitivity and glucose metabolism, which creates genuine management challenges for people on diabetes medications. Research shows that melatonin can affect blood sugar levels in both directions depending on individual circumstances — potentially increasing insulin sensitivity in some contexts while raising fasting glucose in others. The Mayo Clinic advises all people taking diabetes medications to consult a doctor before using melatonin, noting that monitoring blood glucose more frequently after starting melatonin is often appropriate. The practical concern is that glucose fluctuations during overnight sleep — when monitoring is limited — are harder to detect and correct promptly.

Immunosuppressant medications present a different mechanism of concern. Melatonin has documented immune-stimulating properties; it can activate immune function and increase white blood cell production. This creates a direct theoretical conflict with immunosuppressants used after organ transplantation or for autoimmune conditions, where the goal is precisely to dampen immune activity. Mayo Clinic states that melatonin can interfere with immunosuppressive therapy, and advises against use in people with autoimmune disorders. Commonly affected drugs include cyclosporine (Sandimmune), tacrolimus (Prograf), mycophenolate (CellCept), and azathioprine (Imuran). For transplant patients, this is not a category to experiment with independently — prescriber guidance is essential.

7. Starting Low: Why Dose Precision Matters When You're on Medication

If you are on any of the drug categories discussed above and your prescriber has cleared you to try melatonin, the next most important factor is dose. Most over-the-counter melatonin products in North America come in 5mg, 10mg, or even 20mg doses — far above the 0.3–1.5mg range that most sleep researchers consider physiologically relevant for circadian signalling. Higher doses do not necessarily improve sleep outcomes, but they do substantially increase the concentration of melatonin competing for CYP1A2 — which magnifies interaction risk. Starting at the lowest effective dose is not just a general recommendation; for people on interacting medications, it is a genuine safety principle.

This is where formulation matters practically. BioAbsorb Liposomal Liquid Melatonin is designed around precise, low-dose delivery. Each full dropper provides 1.5mg, but the graduated dropper allows increments of approximately 0.25mg — meaning someone starting cautiously can begin at 0.25–0.5mg and titrate up over several nights only if needed and with prescriber awareness. At that dose range, the burden on CYP1A2 is substantially lower than a 5mg or 10mg tablet, which may reduce interaction magnitude for people in moderate-interaction categories. Standard tablets provide no equivalent dose granularity.

The liposomal delivery mechanism also changes the pharmacokinetic picture. BioAbsorb's liposomal technology achieves 80–95% bioavailability compared to 15–20% for standard oral tablets, with onset in 15–30 minutes versus 60–90 minutes for tablets. The faster clearance of a lower, more bioavailable dose may reduce the window during which melatonin is competing with other medications for the same metabolic pathway. BioAbsorb is GMP-certified, manufactured in a Health Canada-approved Canadian facility, and third-party tested on every batch — with a Certificate of Analysis available on request — which provides the dosing accuracy and consistency that matters most when managing interactions carefully.

Frequently Asked Questions

Can I take melatonin with antidepressants?

It depends entirely on which antidepressant. Research confirms that fluvoxamine (Luvox) can increase melatonin blood levels by up to 17-fold by blocking the CYP1A2 enzyme — making this combination potentially dangerous without prescriber guidance. By contrast, citalopram (Celexa), which does not inhibit CYP1A2, showed no effect on melatonin levels in the same study. Never assume all antidepressants carry the same interaction risk; ask your prescriber or pharmacist specifically about your drug's CYP1A2 profile before starting melatonin.

Is melatonin safe with warfarin (blood thinners)?

Caution is warranted. Melatonin can reduce plasma coagulation factors and enhance the blood-thinning effects of warfarin, as documented in a 10-patient case series that showed elevated INR and prothrombin time in most concurrent users. Clinical pharmacists note that no life-threatening bleeds have been reported from this interaction, but more frequent INR monitoring is typically recommended when starting or stopping melatonin while on warfarin. Inform your prescriber before adding melatonin and watch for any unusual bruising or bleeding.

Can melatonin raise blood pressure?

In most people, melatonin mildly lowers blood pressure. However, in people taking the calcium channel blocker nifedipine, melatonin can interfere with the drug's mechanism and cause blood pressure to rise — with one study documenting a 6.5 mmHg increase in systolic pressure. The Mayo Clinic advises anyone on blood pressure medication to discuss melatonin with their prescriber first and monitor blood pressure more closely after starting it.

How many melatonin drug interactions are there?

Drugs.com's interaction database lists 354 drugs known to interact with melatonin — 5 major interactions, 340 moderate, and 9 minor — plus 3 disease-based interactions and 1 food/alcohol interaction. This broad profile exists because melatonin is metabolized through the CYP1A2 pathway, which is shared with dozens of prescription drugs. It does not mean melatonin is dangerous for everyone on medication; it means every individual's medication list deserves a specific pharmacist review before starting melatonin.

What is the safest dose of melatonin if I'm on medication?

Most sleep researchers recommend starting at the lowest effective dose — often 0.3–0.5mg — rather than the 5–10mg doses common in standard OTC products. Lower doses reduce the burden on the CYP1A2 enzyme, which may reduce interaction magnitude. A liquid formulation with a graduated dropper, such as BioAbsorb Liposomal Liquid Melatonin, allows sub-milligram dosing that standard tablets cannot provide. Always disclose melatonin use to your prescriber and pharmacist when starting or stopping — both transitions can affect medication monitoring.

Does my pharmacist know about melatonin drug interactions?

Yes — and a pharmacist is often the most accessible resource for a comprehensive interaction check. Pharmacists have access to professional drug interaction databases and can screen your complete medication list for CYP1A2 conflicts and pharmacodynamic overlaps in a single visit. The NIH's NCCIH specifically recommends this step for all medication users before starting melatonin — and it typically takes under five minutes at your pharmacy counter.

Conclusion

Melatonin's OTC status makes it easy to underestimate. With 354 documented drug interactions — 5 of them major — it is one of the more pharmacologically active supplements in common use. The highest-priority categories to review are antidepressants (especially fluvoxamine), blood thinners, blood pressure medications (particularly nifedipine), sedatives, diabetes drugs, and immunosuppressants. For anyone navigating these medication categories, a pharmacist conversation is the single most effective first step — and starting at a precisely controlled low dose matters as much as the conversation itself. If you have been cleared to try melatonin, BioAbsorb Liposomal Liquid Melatonin's graduated dropper gives you the sub-milligram dose control that most medication users need.

Research References

1. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects — an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European Journal of Clinical Pharmacology, Vol. 56 (2000). Demonstrated that fluvoxamine's CYP1A2 inhibition markedly raises melatonin levels while citalopram — a CYP1A2-neutral SSRI — does not; establishes that antidepressant interaction risk is enzyme-specific, not class-wide.
2. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. Journal of Pineal Research, Vol. 44(2) (2008). Found that oral melatonin lowered plasma procoagulant factors with evidence of a dose-response relationship, supporting the clinical caution around combining melatonin with anticoagulant medications.
3. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. British Journal of Clinical Pharmacology, Vol. 56 (2003). Clinical pharmacokinetic study in 12 healthy subjects showing that caffeine co-administration increased melatonin Cmax by 137% and AUC by 120%, confirming CYP1A2 as the principal metabolic pathway and caffeine as a clinically relevant inhibitor.
4. Current insights into the risks of using melatonin as a treatment for sleep disorders in older adults. Clinical Interventions in Aging, Vol. 18 (2023). Systematic review of 2,130 patients; most common adverse effects vs placebo were daytime sleepiness (1.66%), headache (0.74%), and dizziness (0.74%) — all mild; underscores melatonin's generally favourable safety profile at standard doses.
5. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurology International, Vol. 15 (2023). Narrative review concluding that melatonin at doses of approximately 5–6 mg/day or less appears safe for long-term use, with research generally finding no difference from placebo on negative outcome measures.
6. Melatonin. StatPearls, NCBI Bookshelf (Updated 2024). Authoritative clinical reference documenting that melatonin undergoes first-pass hepatic metabolism via CYP1A2 with over 80% of an oral dose excreted as inactive 6-sulfatoxymelatonin; outlines special population considerations including hepatic impairment and dialysis.
7. Melatonin: What You Need to Know. National Center for Complementary and Integrative Health (NCCIH), NIH (2023). Federal health authority guidance recommending medical supervision for melatonin use in people with epilepsy or on blood thinners, and pharmacist review for all medication users before starting melatonin.
8. Melatonin drug interactions — interaction checker. Drugs.com. Pharmacist-reviewed database documenting 354 known melatonin drug interactions (5 major, 340 moderate, 9 minor), constituting the most comprehensive publicly available interaction count for melatonin.
9. 9 Melatonin Interactions to Be Aware Of. GoodRx, authored by clinical pharmacists (2024). Pharmacist-written clinical summary documenting the nifedipine blood pressure interaction, warfarin coagulation risk, and sedation amplification categories; source for the 6.5 mmHg systolic blood pressure increase figure with nifedipine co-administration.
10. Melatonin. Mayo Clinic. Peer-reviewed institutional drug reference covering all major interaction categories including anticoagulants, anticonvulsants, blood pressure drugs, CNS depressants, diabetes medications, contraceptives, immunosuppressants, and CYP1A2/CYP2C19 substrates.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.